Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ellmark

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Immunology|April 2, 2003
Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosisPeter Ellmark, Christina Furebring, Carl A K Borrebaeck
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human diseasePeter Ellmark, Adrian Woolfson, Larissa Belov, et al.
Journal of Molecular Recognition : JMR|July 1, 2004
A novel mammalian display system for the selection of protein-protein interactions by decoy receptor engagementPeter Ellmark, Mats Ohlin, Carl A K Borrebaeck, et al.
Expert Opinion on Biological Therapy|May 27, 2021
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapyKarin Enell Smith, Adnan Deronic, Karin Hägerbrand, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2016
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulationPeter Ellmark, Sara M Mangsbo, Christina Furebring, et al.
Molecular Immunology|September 11, 2002
In vitro molecular evolution of antibody genes mimicking receptor revisionPeter Ellmark, Olga Esteban, Christina Furebring, et al.
Immunology|August 3, 2002
Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display libraryPeter Ellmark, Camilla Ottosson, Carl A K Borrebaeck, et al.
Pharmacogenomics|August 5, 2006
The application of CD antigen proteomics to pharmacogenomicsAdrian Woolfson, Peter Ellmark, Jeremy S Chrisp, et al.
AIDS Research and Human Retroviruses|March 11, 2008
Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infectionPeter Ellmark, Henrik Andersson, Sisay Abayneh, et al.
Cancer Immunology, Immunotherapy : CII|May 5, 2021
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivoAdnan Deronic, Anneli Nilsson, Mia Thagesson, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Immunology|April 2, 2003
Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosisPeter Ellmark, Christina Furebring, Carl A K Borrebaeck
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human diseasePeter Ellmark, Adrian Woolfson, Larissa Belov, et al.
Journal of Molecular Recognition : JMR|July 1, 2004
A novel mammalian display system for the selection of protein-protein interactions by decoy receptor engagementPeter Ellmark, Mats Ohlin, Carl A K Borrebaeck, et al.
Expert Opinion on Biological Therapy|May 27, 2021
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapyKarin Enell Smith, Adnan Deronic, Karin Hägerbrand, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2016
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulationPeter Ellmark, Sara M Mangsbo, Christina Furebring, et al.
Molecular Immunology|September 11, 2002
In vitro molecular evolution of antibody genes mimicking receptor revisionPeter Ellmark, Olga Esteban, Christina Furebring, et al.
Immunology|August 3, 2002
Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display libraryPeter Ellmark, Camilla Ottosson, Carl A K Borrebaeck, et al.
Pharmacogenomics|August 5, 2006
The application of CD antigen proteomics to pharmacogenomicsAdrian Woolfson, Peter Ellmark, Jeremy S Chrisp, et al.
AIDS Research and Human Retroviruses|March 11, 2008
Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infectionPeter Ellmark, Henrik Andersson, Sisay Abayneh, et al.
Cancer Immunology, Immunotherapy : CII|May 5, 2021
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivoAdnan Deronic, Anneli Nilsson, Mia Thagesson, et al.
Pageof 4